Detalhe da pesquisa
1.
The effects of adding palbociclib to endocrine therapy to treat advanced breast cancer: a plain language summary of a study using the PALOMA-2 and PALOMA-3 trial results.
Future Oncol
; 20(1): 5-16, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37916267
2.
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study.
Lancet Oncol
; 22(2): 212-222, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33460574
3.
Prognostic Factors for Overall Survival in Patients with Hormone Receptor-Positive Advanced Breast Cancer: Analyses From PALOMA-3.
Oncologist
; 26(8): e1339-e1346, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34037282
4.
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Oncologist
; 26(5): e749-e755, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33486783
5.
Efficacy and safety of palbociclib plus endocrine therapy in North American women with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.
Breast J
; 26(3): 368-375, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-31448513
6.
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.
Lancet Oncol
; 17(4): 425-439, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26947331
7.
Effect of palbociclib plus endocrine therapy on time to chemotherapy across subgroups of patients with hormone receptorâpositive/human epidermal growth factor receptor 2ânegative advanced breast cancer: Post hoc analyses from PALOMA-2 and PALOMA-3.
Breast
; 66: 324-331, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36463643
8.
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03).
J Clin Oncol
; 40(5): 449-458, 2022 02 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34995105
9.
Predictors of prolonged benefit from palbociclib plus fulvestrant in women with endocrine-resistant hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in PALOMA-3.
Eur J Cancer
; 104: 21-31, 2018 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-30308388